Viking Therapeutics Shares Drop Over 30% Amidst Obesity Trial Setbacks
TL;DR Summary
Viking Therapeutics' stock dropped 37% after revealing that its obesity drug VK2735 had a high dropout rate in a Phase 2 trial, despite showing some efficacy in weight loss. The high discontinuation rate raised concerns about the drug's tolerability and competitive position compared to Eli Lilly's offerings, leading to investor skepticism about Viking's prospects in the oral obesity market.
- Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Yahoo Finance
- Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data CNBC
- Viking's oral pill reduces up to 12.2% weight but shares slump on higher patient exits Reuters
- Viking Therapeutics (VKTX) Stock Fell More Than 30%. What Sent It Crashing. Barron's
- Viking Therapeutics loses a third of its value after oral weight-loss drug trial MarketWatch
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 2 min read
Condensed
85%
382 → 59 words
Want the full story? Read the original article
Read on Yahoo Finance